Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 4
1989 3
1990 1
1991 5
1992 4
1993 3
1994 2
1995 3
1996 1
1997 6
1998 8
1999 6
2000 1
2001 3
2002 4
2003 3
2004 4
2005 6
2006 5
2007 14
2008 16
2009 13
2010 17
2011 20
2012 19
2013 24
2014 35
2015 44
2016 32
2017 40
2018 52
2019 37
2020 45
2021 45
2022 42
2023 41
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

528 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents.
Neu A, Bürger-Büsing J, Danne T, Dost A, Holder M, Holl RW, Holterhus PM, Kapellen T, Karges B, Kordonouri O, Lange K, Müller S, Raile K, Schweizer R, Sengbusch SV, Stachow R, Wagner V, Wiegand S, Ziegler R. Neu A, et al. Among authors: holl rw. Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S39-S72. doi: 10.1055/a-1018-8963. Epub 2019 Dec 20. Exp Clin Endocrinol Diabetes. 2019. PMID: 31860926 Free article. Review. No abstract available.
Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group.
Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Fleming GA, et al. Among authors: holl rw. Diabetes Care. 2020 Jan;43(1):250-260. doi: 10.2337/dci19-0062. Epub 2019 Dec 5. Diabetes Care. 2020. PMID: 31806649 Review.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: holl rw. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Use Existing Registry.
Holl RW, Wölfle J. Holl RW, et al. Dtsch Arztebl Int. 2021 Jul 12;118(27-28):485. doi: 10.3238/arztebl.m2021.0202. Dtsch Arztebl Int. 2021. PMID: 34491163 Free PMC article. No abstract available.
Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.
Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, Boettcher C, Kapellen T, Rosenbauer J, Holl RW. Karges B, et al. Among authors: holl rw. JAMA. 2017 Oct 10;318(14):1358-1366. doi: 10.1001/jama.2017.13994. JAMA. 2017. PMID: 29049584 Free PMC article.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Among authors: holl rw. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
Diabetes and Road Traffic.
Ebert O, Bohn B, Bertram B, Buchberger B, Finck H, Hoß J, Hübner P, Krabbe L, Kulzer B, Küstner E, Lachenmayr B, Lemmen KD, Petry F, Rinnert K, Salomon M, Schütt W, Holl RW. Ebert O, et al. Among authors: holl rw. Exp Clin Endocrinol Diabetes. 2022 Sep;130(S 01):S137-S150. doi: 10.1055/a-1624-3655. Epub 2022 Apr 22. Exp Clin Endocrinol Diabetes. 2022. PMID: 35453153 No abstract available.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: holl rw. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Diabetes and Road Traffic.
Ebert O, Bohn B, Bertram B, Buchberger B, Finck H, Hoß J, Hübner P, Krabbe L, Kulzer B, Küstner E, Lachenmayr B, Lemmen KD, Petry F, Rinnert K, Salomon M, Schütt W, Holl RW, Maxeiner S, Wagener W. Ebert O, et al. Among authors: holl rw. Exp Clin Endocrinol Diabetes. 2024 Feb 23. doi: 10.1055/a-2166-6928. Online ahead of print. Exp Clin Endocrinol Diabetes. 2024. PMID: 38395055 No abstract available.
528 results